Abstract:Abstract Defining the mechanisms that control the perinatal switch from γ-globin (HBG1 and HBG2) to β-globin (HBB) gene expression in human red blood cells (RBCs) has informed novel approaches to reactivate fetal hemoglobin (HbF, α2γ2) therapeutically for sickle cell disease and β-thalassemia. However, one longstanding unsolved problem is to explain how HbF becomes elevated in conditions such as blood loss, hypoxia and hemolysis. These conditions are associated with accelerated RBC production, also referred to as stress erythropoiesis, driven by activation of hypoxia-inducible factor (HIF) via a canonical O 2 sensing pathway. At high O 2 levels ("normoxia"), O 2-dependent prolyl hydroxylase domain (PHD) enzymes hydroxylate HIFα, thereby targeting it for ubiquitination by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, followed by proteasomal degradation. At low O 2 tension (hypoxia), PHD activity is reduced, causing HIF1α to accumulate, dimerize with constitutively expressed HIF1β, and bind hypoxia response elements (HREs) to activate a broad array of genes that facilitate hypoxic adaptation. We identified VHL and HIF1α, as negative and positive regulators of HbF expression, respectively. Disruption of the VHL gene in CD34 + hematopoietic stem and progenitor cells (HSPCs) by transfection with ribonucleoprotein (RNP) consisting of Cas9 and VHL-targeting guide RNA increased HbF expression from 7.5% ±1.2% in control cells to 30.9% ± 4.8% (mean ± SD, P<0.0001) in RBC progeny generated by in vitro differentiation. Similarly, γ-globin mRNA was induced by 5 -fold after disruption of VHL in HUDEP-2 cells, an immortalized erythroid line that expresses mainly adult hemoglobin (HbA, α2/β2). Mass spectrometry and transcriptome analysis of VHL-disrupted CD34 + HSPCs revealed increased HIF1α protein expression with no change in the corresponding mRNA. Inhibition of HIF1A mRNA by RNA interference suppressed γ-globin induction in VHL-/- HUDEP-2 clones and in RBCs generated from VHL RNP-treated CD34 + cells, indicating VHL knockout induced HbF through HIF1α protein accumulation. CUT&RUN analysis of VHL-depleted erythroblasts revealed HIF1α/HIF1β heterodimer occupancy at BGLT3, a long-noncoding RNA locus approximately 2.7kb 3' of HBG1. The HIF1α-bound BGLT3 locus contains two canonical HREs (ACGTG) separated by 13 bp. Disruption of each HRE motif in VHL-/- HUDEP-2 cells by base editing caused additive reductions in BGLT3 HIF1α occupancy and γ-globin expression. Mechanistically, VHL depletion caused the accumulation of HIFα/β heterodimers at BGLT3, recruitment of the transcriptional activators GATA1 and P300, and targeted chromatin accessibility to establish the active enhancer mark H3K27ac. These changes were accompanied by altered chromosome conformation to favor long-range interactions between the γ-globin loci (HBG1 and HBG2) and the locus control region, a powerful upstream enhancer. Treatment of healthy donor CD34 + HSPCs-derived erythroblasts with the clinically approved PHD inhibitor FG-4592 (Roxadustat) caused HbF to increase from 4.76%±1.22% at baseline to 12.86 ± 2.40% (mean ± SD in 3 biological replicates, P<0.01). Treatment of the same erythroblasts with FG-4592 and hydroxyurea, a widely used SCD drug that acts partly by inducing HbF, caused HbF to increase from 4.76% ± 1.22% at baseline to 24.1% ± 5.3% (mean ± SD in 3 biological replicates, P<0.01), indicating an additive effect. Our findings link developmental globin gene regulation with O 2 sensing, provide a mechanism for HbF induction during stress erythropoiesis, and identify a novel therapeutic approach for β-hemoglobinopathies. Disclosures Blobel: Pfizer: Consultancy; Fulcrum Therapeutics, Inc.: Consultancy. Weiss: Beam Therapeutics: Current holder of stock options in a privately-held company; Forma Therapeutics: Consultancy; Cellarity Inc.: Consultancy; Novartis: Consultancy.

The NOTCH1-dependent HIF1α/VGLL4/IRF2BP2 Oxygen Sensing Pathway Triggers Erythropoiesis Terminal Differentiation.

Zebrafish ELL-associated Factors Eaf1/2 Modulate Erythropoiesis Via Regulating Gata1a Expression and WNT Signaling to Facilitate Hypoxia Tolerance

Deletion of the foxO1 gene reduces hypoxia tolerance in zebrafish embryos by influencing erythropoiesis

Gfi1aa/Lsd1 Facilitates Hemangioblast Differentiation into Primitive Erythrocytes by Targeting Etv2 and Sox7 in Zebrafish.

Zebrafish mutants in egln1 display a hypoxic response and develop polycythemia

Hif-1α and Hif-2α regulate hemogenic endothelium and hematopoietic stem cell formation in zebrafish

Mutations in the zebrafish hmgcs1 gene reveal a novel function for isoprenoids during red blood cell development

Single-cell analyses demonstrate that a heme-GATA1 feedback loop regulates red cell differentiation

Deletion of the Foxo4 Gene Increases Hypoxia Tolerance in Zebrafish.

Creg1 Regulates Erythroid Development Via TGF‐β/Smad2‐Klf1 Axis in Zebrafish

Blf and the Drl Cluster Synergistically Regulate Cell Fate Commitment During Zebrafish Primitive Hematopoiesis

Regulation of Fetal Hemoglobin Expression By the VHL-HIF1α Oxygen Sensing System

Vitreoscilla Hemoglobin (VHb) Overexpression Increases Hypoxia Tolerance in Zebrafish ( Danio rerio )

Cell-specific transcriptional control of mitochondrial metabolism by TIF1γ drives erythropoiesis

The Zebrafish Mir‐462/mir‐731 Cluster is Induced under Hypoxic Stress Via Hypoxia‐inducible Factor 1α and Functions in Cellular Adaptations

Identification Of Hif-1 Alpha Promoter And Expression Regulation Of Hif-1 Alpha Gene By Lps And Hypoxia In Zebrafish

A Regulatory Circuit Comprising GATA1/2 Switch and Microrna-27A/24 Promotes Erythropoiesis.

HEMATOPOIESIS AND STEM CELLS Aggf 1 acts at the top of the genetic regulatory hierarchy in speci fi cation of hemangioblasts in zebra fi sh

Identification of HIF - 1α promoter and expression regulation of HIF - 1α gene by LPS and hypoxia in zebrafish

Functional conservation of erythropoietin signaling in zebrafish

Bhlhe40 limits proliferation and prevents excessive angiogenesis in mouse embryoid bodies under hypoxia